Goetze, Sandra http://orcid.org/0000-0001-6880-8020
Schüffler, Peter
Athanasiou, Alcibiade
Koetemann, Anika
Poyet, Cedric
Fankhauser, Christian Daniel
Wild, Peter J.
Schiess, Ralph
Wollscheid, Bernd http://orcid.org/0000-0002-3923-1610
Funding for this research was provided by:
innosuisse - schweizerische agentur für innovationsförderung (KTI 16771.3, KTI 16771.3, KTI 16771.3)
personalized health and related technologies strategic focus area of eth (PHRT 0-21411-18)
schweizerischer nationalfonds zur förderung der wissenschaftlichen forschung (31003A_160259)
Swiss Federal Institute of Technology Zurich
Article History
Received: 30 July 2021
Accepted: 5 April 2022
First Online: 27 April 2022
Declarations
:
: The Ethics Committee of the Kanton Zurich, Switzerland, approved all procedures involving human material, and all patients gave informed consent (Ref. Nr. StV KEK‐ZH‐Nr. 06/08).
: Not applicable.
: P.J.W. has received consulting fees and honoraria (private/institutional) for lectures by Bayer, Janssen-Cilag, Novartis, Roche, MSD, Astellas Pharma, Bristol-Myers Squibb, Thermo Fisher Scientific, Molecular Health, Sophia Genetics, Qiagen, Eli Lilly, and AstraZeneca. A.A. and R.S. are inventors of the following patent application (WO2018011212, Method of detecting proteins in human samples and uses of such methods) as well as R.S. on patent application (WO2009138392, Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith). R.S. is co-founder of Proteomedix. Authors A.A. and R.S. are employed by Proteomedix and hold stock options, while R.S. holds founder shares of Proteomedix.